Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Non-Current Deffered Revenue (2017 - 2022)

Q32 Bio (QTTB) has 6 years of Non-Current Deffered Revenue data on record, last reported at $354000.0 in Q1 2022.

  • For Q1 2022, Non-Current Deffered Revenue fell 90.06% year-over-year to $354000.0; the TTM value through Mar 2022 reached $354000.0, down 90.06%, while the annual FY2021 figure was $1.2 million, 96.4% down from the prior year.
  • Non-Current Deffered Revenue reached $354000.0 in Q1 2022 per QTTB's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $32.1 million in Q4 2020 and bottomed at $354000.0 in Q1 2022.
  • Average Non-Current Deffered Revenue over 5 years is $14.8 million, with a median of $9.5 million recorded in 2018.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 3154.3% in 2018, then tumbled 96.4% in 2021.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $9.5 million in 2018, then grew by 0.78% to $9.5 million in 2019, then skyrocketed by 236.79% to $32.1 million in 2020, then crashed by 96.4% to $1.2 million in 2021, then crashed by 69.38% to $354000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $354000.0 in Q1 2022, $1.2 million in Q4 2021, and $2.0 million in Q3 2021.